Sun Pharma gets USFDA nod for caffeine citrate oral solution
Sun Pharmaceutical Industries, the country`s most valued drug maker, has received final approval from the US Food and Drug Administration (USFDA) to market caffeine citrate solution in the strength of 30 mg/3 ml.
Caffeine citrate is indicated for short term treatment of apnea in premature infants between 28 and less than 33 weeks gestational age.
Caffeine citrate is the only drug approved by USFDA for the short-term (10-12 days) treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age.
October 09, 2009